Patent court to review Alexion's Soliris patents on Amgen challenge: filings
Reuters: Health
The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment